1st European CAR T Cell Meeting
14 Février 2019 - 16 Février 2019
France
The recent approval of the first CAR T cell treatments in Europe presents a great opportunity to fight hematological malignancies but also poses serious challenges given the peculiar nature of the treatment. Patients, physicians, nurses, hospitals and whole health systems need to learn how to select the right treatments, handle specific toxicities, organize treatment units and cope with the increasing costs connected with CAR T therapy.
The European CAR T Meeting provides the ideal context to meet these learning objectives, with speakers who will share first-hand experience, including presenters from the United States who pioneered the field and representatives of the EU-funded projects CARAMBA (https://www.caramba-cart.eu(s’ouvre dans une nouvelle fenêtre)) and EURE-CART (http://www.eure-cart.eu(s’ouvre dans une nouvelle fenêtre)). The programme includes a comprehensive outlook on the current research efforts to increase CAR T cell therapies efficacy and targets, with input from basic researchers as well as representatives from the industry.
This meeting will cover the following topics:
• Pre-clinical pipeline: novel CAR technologies and targets,
• CAR T therapies currently tested and used in the clinics,
• Safety/clinical management of CAR T patients,
• Optimal patient selection for treatment with CAR T,
• Industry perspective and hospital perspective in manufacturing and administering CAR T,
• Practical solutions in the handling of apheresis and clinical application of CAR T cells,
• Nurses training,
• Regulatory aspects, health economics, and reimbursement for CAR T, and
• Centre Qualification, documentation and implementation of a quality management system.
Chair: H Einsele, C Chabannon
Co-chair: M Hudecek (coordinator CARAMBA project)
With key-note lectures: Carl June, Michel Sadelain and Stanley Riddell
For the complete programme, please visit:
EHA website https://ehaweb.org/meetings/swg-immunotherapy/scientific-program/(s’ouvre dans une nouvelle fenêtre)
or the EBMT website https://www.ebmt.org/events/1st-european-car-t-cell-meeting(s’ouvre dans une nouvelle fenêtre)
The European CAR T Meeting provides the ideal context to meet these learning objectives, with speakers who will share first-hand experience, including presenters from the United States who pioneered the field and representatives of the EU-funded projects CARAMBA (https://www.caramba-cart.eu(s’ouvre dans une nouvelle fenêtre)) and EURE-CART (http://www.eure-cart.eu(s’ouvre dans une nouvelle fenêtre)). The programme includes a comprehensive outlook on the current research efforts to increase CAR T cell therapies efficacy and targets, with input from basic researchers as well as representatives from the industry.
This meeting will cover the following topics:
• Pre-clinical pipeline: novel CAR technologies and targets,
• CAR T therapies currently tested and used in the clinics,
• Safety/clinical management of CAR T patients,
• Optimal patient selection for treatment with CAR T,
• Industry perspective and hospital perspective in manufacturing and administering CAR T,
• Practical solutions in the handling of apheresis and clinical application of CAR T cells,
• Nurses training,
• Regulatory aspects, health economics, and reimbursement for CAR T, and
• Centre Qualification, documentation and implementation of a quality management system.
Chair: H Einsele, C Chabannon
Co-chair: M Hudecek (coordinator CARAMBA project)
With key-note lectures: Carl June, Michel Sadelain and Stanley Riddell
For the complete programme, please visit:
EHA website https://ehaweb.org/meetings/swg-immunotherapy/scientific-program/(s’ouvre dans une nouvelle fenêtre)
or the EBMT website https://www.ebmt.org/events/1st-european-car-t-cell-meeting(s’ouvre dans une nouvelle fenêtre)
Mots‑clés
CAR-T, hematology, myeloma, leukemia